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Background: The study was done to assess the feasibility of conducting a trial evaluating the use of an intradialytic
oral nutritional supplement (ONS) on nutritional status.
Methods: The study design is a single centre, parallel group, external pilot randomised controlled trial (RCT). The
setting was at a haemodialysis unit in Sheffield, UK. The aim was to recruit 30 trial participants to allow at least 12
evaluable patients per arm, but the actual study sample consisted of 10 adults with a body mass index (BMI) ≤22 kg/m2,
receiving thrice weekly haemodialysis. All participants received nutritional advice from a renal dietitian as per usual
practice. The intervention included the provision of an intradialytic ONS. Feasibility outcomes included recruitment to
time and retention of participants along with palatability of ONS. Secondary outcomes were clinical parameters to
obtain variance and estimates of effect size to inform the sample size calculation for a definitive trial.
Results: Recruitment was undertaken for a fixed period of 6 weeks. Rates were lower than expected mainly due to
ineligibility with only 7% of screened patients (19/265) being eligible and 4% (10/265) of these being recruited. Due to
the small proportion of patients eligible for the trial, all haemodialysis patients at the specified unit were assessed for
eligibility. Data completion rates were low for session questionnaires (23%). Sample sizes derived from variance in
secondary outcome measure of handgrip strength and adjusted for a dropout rate of 20% indicate that 189 patients
would be required for a definitive RCT, requiring 19 UK haemodialysis units to participate.
Conclusions: A definitive RCT is feasible with some adaptation to exclusion criteria and methodology. The exclusion
criteria could be adapted to include an increase in upper limit for BMI. The use of questionnaires at each dialysis
session may not be feasible but the inclusion of appetite and supplement consumption data collection at the main
assessments would provide similar outcome data. Quality of life assessment using SF-12 would be acceptable.
Trial registration: ISRCTN37431579.
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Malnutrition is reportedly present in 20%–50% of the
haemodialysis population [1-4]. It can be described as a
nutrient intake lower than the nutritional needs of the
individual [1] and contributes to protein and energy
wasting (PEW). This has many consequences, including
increased mortality and morbidity, decreased quality of
life (QOL) and increased risk of hospitalisation [1,4].
Causes of malnutrition in the haemodialysis popula-
tion are multifactorial but include a decreased appetite
and oral intake due to uraemic toxins [5], protein losses
on dialysis [6] and the catabolic effect of dialysis [7,8].
Interventions to improve nutritional status and prevent
malnutrition, through an increase in nutrient intake, in-
clude the following: dietary counselling [9,10], the use of
oral nutritional supplements and enteral or parenteral nu-
trition [11]. These interventions have shown to improve
various markers of nutritional status in some way but
focus on implementation at home rather than during dia-
lysis, potentially indicating a missed opportunity for nutri-
tional support [12].
UK patients receive on average 3–4 h of haemodialy-
sis, three times per week, and it is this period of time
that was explored within this study as a potential means
of improving nutritional status by administering an oral
nutritional supplement (ONS).
The measurement of nutritional status is difficult and
should be classified using a variety of reproducible mea-
sures that predict outcome [10]. Previous studies meas-
uring the impact of ONS given to haemodialysis patients
have used albumin [13,14], subjective global assessment
(SGA) [15,16], QOL [16,17] and anthropometric mea-
sures [18]. Handgrip strength (HGS) is also an emerging
measure of nutritional status [19,20]. Many of the previ-
ous studies recommend the need for further research as
the type of nutritional support, the timing of ingestion
and which nutritional markers should be used to best
assess their efficacy are still not clear. This pilot trial ex-
plores some of these parameters and will lead to a more
robust definitive trial in the future.
Methods
The aim of this study was to conduct a randomised con-
trolled external pilot trial of the feasibility of undertaking
a study to assess the effect of an intradialytic ONS on
the nutritional status of haemodialysis patients [21].
Feasibility outcomes included recruitment to time, re-
tention of participants, barriers to recruitment and pal-
atability of ONS. Secondary outcome measures related
to the estimation of a sample size for a definitive trial.
Ethical approval was received after a full review by
the National Research Ethics Service Committee. Re-
search governance approval was provided by the spon-
soring trust.Setting: A large adult haemodialysis unit in Sheffield,
UK.
Inclusion criteria
 Adult haemodialysis patients (18 years+)
 Received dialysis for at least 6 months
 Haemodialysis at least three times per week at the
main haemodialysis unit (not satellite centre)
 BMI ≤22 kg/m2
Exclusion criteria
 Amputees
 Patients with significant oedema
 Patients who do not speak fluent English
 Receiving nutritional supplementation prior to study
commencing or within 1 month commencement in
study
 Known allergies to any ingredients in the ONS
 Those with persistent hyperkalaemia or
hyperphosphataemia (defined as the last 3 months)
Outcomes
The primary outcome was the recruitment rate, calculated
as the proportion of those screened and consented to par-
ticipate in the trial within 6 weeks (a fixed recruitment
window). Barriers to recruitment, the impact of excluding
non-fluent English speakers and the acceptability of a nu-
tritional intervention study protocol in a UK haemodialysis
population were assessed.
Patient preference, palatability of ONS and compliance
with the intervention were recorded using a questionnaire
completed at each dialysis session and the completion rate
of these questionnaires was assessed. QOL was assessed
using the SF12-V2® [22] along with the acceptability of
using this tool.
Secondary outcomes were clinical endpoints related
to the effect of intradialytic ONS on nutritional status:
HGS, QOL, weight and dietary intake. Secondary out-
comes were measured at baseline, after 1 month and at
the end of the trial (2 months after randomisation).
These outcomes helped determine the most appropriate
outcome measures and timing of data collection points
for a larger randomised controlled trial (RCT) and in-
formed the sample size calculation.
Sample size
This trial was designed to collect data to inform the
sample size calculations for a future definitive RCT. The
primary outcome was recruitment within a fixed time
window of 6 weeks, chosen based on practical consider-
ations such as time and the size of the research team
(one data collector) along with estimates of attendance
of eligible patients at the recruiting unit. It was estimated
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30. A sample size of 12 evaluable patients per arm
would give appropriate precision for the sample size
estimates [21,23].Randomisation and blinding
Participants were randomised to treatment group via a
web-based randomisation system provided by a University
of Sheffield subsidiary software development company,
epiGenesys. This took place at the time of recruitment
and was actioned by the main author. The allocated treat-
ment (ONS or standard care) was only disclosed after par-
ticipants’ details had been recorded and entered in the
trial. Randomisation was stratified by gender and age of
participant with this stratification list provided by the third
author. It was not possible to blind allocation of treatment
for patients or clinicians as the manufacture of a placebo
ONS would be difficult, and one of the aims of the study
was to assess palatability of different ONS to inform how
to maximise compliance in a definitive RCT.
All participants received information from a renal
dietitian as per standard treatment and continued to at-
tend their usual haemodialysis sessions at a frequency of
three times per week.Data collection
Logs of patients screened and approached to participate
were completed to inform possible recruitment rates for
future studies. The time taken to approach patients, request
consent and to conduct each assessment was also logged.
Anonymised basic details were collected from all potentially
eligible patients to allow completion of a CONsolidated
Standards Of Reporting Trials (CONSORT) flow chart.
Diet histories were taken using a 48-h recall method,
and the accuracy enhanced through the use of a food
picture resource [24]. This was then analysed using,
“Microdiet”® version 2.8.8, and a daily average of total
calories, protein, potassium and phosphate was obtained
from the recall.
The HGS was measured in the non-dominant arm
with the exception of those with their functioning vascular
access in that arm. The participant was in a seated position
with the elbow at a 90° angle. HGS was measured three
times using a hydraulic hand dynamometer, with no rest
period between the tests and then an average calculated.
Routine blood tests along with post dialysis weights
were recorded. The SF-12v2® Health Survey [22] was
completed by the participants along with the session
questionnaires. The session questionnaires assessed
the general wellbeing of the participant and the choice
of snack eaten on dialysis, and for those allocated to
the intervention group, it included the choice of ONS,
amount consumed and palatability. The final sessionquestionnaire additionally included some short questions
related to the ease of completion of the QOL assessment.
The intervention was the ingestion of one ONS per
dialysis session over a 2-month period. The ONS varied
in format and nutritional composition but each provided
between 200 and 300 kcal and 10.5–12 g protein. Previ-
ous studies suggest this level of supplementation would
go some way to offsetting the haemodialysis losses [12,25].
Formats included pudding style supplements and milk-
shake type formulas.
Statistical analysis
Data from all randomised patients was analysed. Means,
ranges and standard deviations were reported for the
outcome measures of time taken for assessments, base-
line characteristics, handgrip strength, dietary intake,
QOL and weight. The trial was not powered to enable
statistical comparisons to be performed between groups.
Results
The primary outcome was the proportion of patients
screened in a 6-week period that consented and were
randomised. Recruitment of t = 6 weeks was met but the
original target of recruiting 30 participants (12 evaluable
patients per arm) was not fulfilled. The CONSORT flow
diagram (Figure 1) depicts the numbers of participants
screened and eligible.
The whole haemodialysis population within the speci-
fied centre was screened for eligibility. In total ten par-
ticipants were recruited, five to each arm of the trial.
This represents a proportion of 4% of patients screened
(10/265) that were eligible and consented to participate
in the trial.
It is important to highlight that the population we
were recruiting from was a prevalent, relative fixed size
population and not a presenting population. Prior to the
start of the trial, it was anticipated that recruitment and
conduct of the trial within the time window would limit
the proportion of patients that could be screened. As so
few were eligible, 100% of patients were in actuality
screened. This demonstrates that participant recruitment
cannot be defined by the number of weeks the site is
open to recruitment. Further eligible participants would
need to be awaited with an extended recruitment time.
The eligibility criteria of being on dialysis for at least
6 months is likely to be the only factor to change the
number of eligible participants over time.
Only 7.2% (19/265) of the screened population were
eligible for recruitment to the trial. The majority of
those who were ineligible (71.4%) were excluded due to
their BMI being >22 kg/m2. The mean BMI of the
screened population was 26 kg/m2, with a range of
14–52 kg/m2. The second greatest reason for exclusion
was raised potassium or phosphate level for the previous
Enrolment
Assessed for eligibility, n = 265
Excluded (n=255) 
Not meeting inclusion criteria = 246
Declined to participate = 9
Other reasons = 0
Randomised, n = 10
Allocation
Allocated to intervention, n= 5
Received allocated intervention = 3 
Did not receive allocated intervention = 2 
Allocated to control group, n= 5 
Lost to follow-up, n= 1 (Participant withdrew)
Discontinued intervention =1 
Analysis
Follow-Up
Analysed, n =5
Intention to treat = 5
Excluded from analysis = 0
Analysed n =,5
Intention to treat = 5
Excluded from analysis = 0 
Lost to follow-up, n= 1 (Participant withdrew)
Figure 1 CONSORT flow diagram.
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ONS in the previous month or at the time of screening
(15.2% or 40/265). The impact of not including non-fluent
English speakers excluded 7.2% (19/265) of the screened
population. There was no clear indication of future lan-
guages that should be included but Urdu, Chinese and
Bengali were the main languages at this centre.
Baseline characteristics of the recruited participants
can be seen in Table 1. Whilst the age and BMI of par-
ticipants is similar between the control and intervention
groups, it can be seen that time on dialysis is consider-
ably different. This is in part due to the small numbersTable 1 Baseline characteristics of participants
Characteristic Allocation Count
BMI in kg/m2 at baseline Treatment 5
Control 5
Age at randomisation Treatment 5
Control 5
Time on dialysis in months Treatment 5
Control 5of participants recruited magnifying the differences in
dialysis vintage.
The time taken to conduct the assessments can be
seen in Table 2. It varied throughout the study with the
initial assessment taking longest due to the consent and
randomisation procedures.
The provision of ONS was intended to be after 30 min
of being on haemodialysis but prior to significant fluid
removal, this was not always achieved but specific data
on this was not recorded.
Two patients withdrew from the trial within the first
month (20%), one from each arm. The control patientMean Standard deviation Range
19.60 1.09 18–21
20.64 0.84 19.9–22
57 23 26–79
63 20 29–83
25 14 6–39
121 125 10–320
Table 2 Time taken for assessments at key time points
Time of assessment Count Mean time taken
in minutes
Standard
deviation
Range in
minutes
Baseline 10 57 16.87 40–90
Month 1 8 35.63 6.23 25–45
Month 2 (study end) 8 38.13 10.33 30–60
Table 3 Sample size estimation based on changes in
handgrip strength
Minimum clinically
important difference (kg)
80%
power
85%
power
90%
power
95%
power
2 450 515 603 745
4 113 129 151 187
6 50 58 67 83
10 18 21 25 30
Type 1 error of 0.05 and standard deviation of 10.705 (calculated from this pilot
sample). Increase by 20% to account for dropout rate.
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wish “to be bothered” whilst on haemodialysis, the pa-
tient withdrew from the treatment arm after 1 month
stating that they could not see any benefit to themselves;
both consented to the continued use of their baseline
data. One additional patient withdrew from the interven-
tion (10%) within the month but allowed data collection
to continue at month 1 and study end. The reason given
was a dislike of the ONS with some associated gastro-
intestinal side effects.
Data completion rates
All participants completed the baseline assessment, and
80% of the control and intervention groups respectively
completed assessments at month 1 and study end. Com-
pletion rates of the session questionnaires were poor
(23.1%) and thus the usefulness of the data is limited.
The completion rates of the QOL tool and its accept-
ability were encouraging. The SF-12v2® [22] was com-
pleted by 100% participants at baseline and 80% at month
1 and study end. Acceptability results indicate that partici-
pants did not feel that it took too long to complete and
were happy to complete each month.
Results from routine blood tests included biochemical
markers used to screen for eligibility and were collected
during patient follow-up. Due to the small sample differ-
ences between groups, these were not analysed but feasi-
bility aspects were highlighted. Coinciding recruitment
of participants with the timing of routine blood tests
was not always possible due to the small research team
or the tests being conducted outside of the expected
window. This had the knock-on effect that results did
not always fit with the timing of the other follow-up as-
sessments, differing by up to 10 days on some occasions.
Outcome measures and sample size for a definitive RCT
The identification of potential outcome measures for a
definitive trial and a sample size calculation were crucial
elements of this pilot trial. HGS proved easy to use, was
accepted by participants and did not result in any ad-
verse events.
Data from the recruited population was used to cal-
culate the required sample size for a definitive trial if
the primary outcome were change in HGS. A range of
possible minimum clinically important differences were
selected from standardised tables of HGS for thegeneral population [26]. See Table 3 for the sample size
estimation.
One hundred eighty-nine participants would be re-
quired, with 90% power and a 4-kg minimal clinically
important difference. This would allow appropriate stat-
istical analysis of the sample whilst the 4 kg was chosen
as a significant change in HGS within a relatively short
space of time, for example 3 months. The sample size is
based on the estimation of 151 participants required as
shown in Table 3 and inflating by 20% to account for the
dropout rate seen in this pilot trial. However, a further
inflation of 10% would be required if a per protocol ana-
lysis was to be conducted as a primary analysis. Based on
these figures and results from this pilot trial, 19 centres
would be required to participate, each with a population
of approximately 250 haemodialysis patients recruiting 10
participants each.
Discussion
The outcomes of this pilot trial focused on feasibility el-
ements, including recruitment to time, eligibility criteria
and sample size estimations with the overall aim of
assessing if it is possible to conduct a definitive trial
within this population.
Recruitment
The target of recruit to time was met but this did not
translate to the expected number of eligible patients be-
ing recruited. Eligibility of the screened population was
much lower than expected, indicating that the inclusion
criteria may have been too stringent.
The exclusion criteria of BMI ≤22 kg/m2 was based on
published evidence that a BMI at the lower end of the
normal range can increase mortality in the haemodialysis
population [27]. However, body composition is thought to
play a much greater role in the protective effects of a
greater BMI, than the BMI itself [28]. The use of BMI as a
screening tool was a quick and easy measure but the level
of ≤22 kg/m2 should be reassessed prior to a definitive
trial. If the BMI was raised to ≤24 kg/m2 then this would
have increased potential recruitment by 10%.
The addition of inclusion criteria such as weight loss
over a specified period of time, HGS or additional
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hance the detection of participants most at risk of
malnutrition.
The exclusion of non-English speakers did contribute
to recruitment issues, but no particular language was
identified to be beneficial to include in future studies.
The exclusion of those with hyperphosphataemia or
hyperkalaemia was a safety precaution for this pilot trial
due to the limited funding and monitoring capabilities.
It may be possible in a larger trial to include these par-
ticipants and monitor the effect that the standard ONS
has on their already elevated potassium and phosphate
levels. The use of a renal-specific ONS, containing re-
duced electrolytes could also be considered for these
participants. If these participants had not been excluded,
an additional 53 patients could potentially have been eli-
gible for the trial—although they may still be ineligible
due to other exclusion criteria.
We would recommend the use of a web-based ran-
domisation system as it was very easy to use, ensured a
reduction of allocation bias and provided an audit trail
of the process, essential for the validity of clinical trials
[29,30]. However, the use of a wireless device should be
considered to potentially reduce the time taken to log
into the system in a dialysis centre setting.
The timing of the intervention was considered in the
trial. The ONS should have been provided after 30 min
of commencing dialysis and before significant fluid re-
moval had commenced with the aim of reducing poten-
tial blood pressure-related side effects [31]. In practice,
ONS were not always provided within the stated time
points, but the exact timing of the supplement was not
recorded. Two patients reported detrimental effects dur-
ing informal discussions having received the ONS to-
wards the end of their dialysis session and felt sick and/
or vomited which had caused them to stop the interven-
tion. There is insufficient evidence to suggest that the
timing of the ONS was the sole cause of this. However,
the use of a prescriptive time period along with a formal
log of the time the ONS was provided would have been
beneficial and is recommended for future studies. The
small sample size prevents definitive timings from being
suggested.
The logistics of matching the monthly blood tests to
the time of recruitment proved difficult, but in a larger
trial, the effect of the blood tests not matching time of
recruitment would be lessened as recruitment time
could be adapted, and with a longer intervention period,
the precise date of the blood tests would be less of a
problem as an average effect could still be elicited.
Data collection
Completion rates of the session questionnaires were very
poor (23.1% completed). During informal discussions,participants reported to frequently forget to complete
them making monitoring of compliance with the inter-
vention difficult to conclude. However, the three partici-
pants in the intervention arm that did not actively stop
taking the ONS reported to not take an ONS every dia-
lysis session as indicated. Reasons for this included for-
getting to ask for an ONS; not being given a supplement
and not feeling like having a supplement at that particu-
lar dialysis session. The average consumption over time
should potentially be assessed rather than individual ses-
sion consumption and could be an additional measure
asked at the specified time points. In addition to this,
the palatability of the ONS could also be assessed on an
average basis. There was no indication within this pilot
to suggest a certain dislike for particular products al-
though it is well known that ONS preferences vary
amongst individuals and the prevention of taste fatigue
with variety is very important.
It is essential that dietary intake is monitored to detect
any changes to intake that may occur as a result of the
ONS. The omission of this monitoring in any definitive
trial foregoes the possibility of detecting change solely
due to the ONS.
The use of 48-h recall as the method of dietary assess-
ment caused some problems with data capture. Many
patients were unable to recall a full 48-h period and
therefore the 48-h recall was a patchwork of meals pro-
viding an average intake. It provided an estimation of
their nutritional intake at the time of the assessment,
but the accuracy would be questionable. This was in
addition to the well-known problems of dietary assess-
ment including over- and underestimation of intake and
the tendency for participants to inform the investigator
of food intake that they feel is correct rather than their
actual intake [32]. Consideration could be given to the
use of an application to record food intake for 2 days
either via a website or on a smart phone. Patients could
then be given the choice of this application, recall with a
trial dietitian or completion of a food diary. The use of
an application or diary would still need verification by a
research team member to accurately assess portion sizes
and to clarify ambiguous entries.
The process of dietary assessment requires significant
skill that is part of a dietitian’s training, so if this task
was to be delegated to another individual within any fu-
ture research teams, it would need careful consideration.
The standardisation of the process is difficult as individ-
uals respond to questions differently and assessments
must not be leading, whilst ensuring that sufficient detail
is gathered to allow dietary analysis to be conducted.
The use of the picture resource [24] facilitated portion
sizes to be clarified with the patient and improved the
accuracy of the assessment along with the ease of input-
ting the data into the dietary analysis package.
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(ITT) basis due to the small sample size. A per protocol
analysis in addition to the ITT would be indicated in a
larger trial.
The SF12-v2® [22] was well received by participants,
but there are however, a few considerations for the
future use of this tool. Some patients needed help to
complete the form due to a number of reasons including
inability to use a pen whilst on dialysis due to their vas-
cular access, forgetting reading glasses and also requiring
help to understand the questions. The use of both a self-
completion and a scripted version of the questionnaire
would have prevented these problems.
The changes in weight, target weight and BMI seen in
this pilot are very small due to the short data collection
period, and their significance cannot be commented
upon due to the small sample size. However, in a longer
definitive trial, they would be useful tools along with
biochemical markers to determine change in nutritional
status [1].
Sample size calculation
The data collected in this pilot trial provided an estimate
to calculate sample sizes needed for a definitive trial.
There was insufficient data to assess true variation and
thus only estimates are provided. These sample size
calculations are given in Table 3. HGS was used to cal-
culate the sample size as this is the most likely outcome
measure for a definitive trial. It would allow an assessment
of body composition change as opposed to weight which
can be affected by other parameters. This change in body
composition is an important factor in nutritional status
and the protective effect of having a greater BMI [28,33].
The change of 2–10 kg in handgrip strength is the
average, but it is difficult to state a significant change as
there are no standard tables for use in the renal popula-
tion. Previous studies have shown correlation between
HGS and other markers of nutritional status [19,20] and
more recently a link with mortality [34], demonstrating
the potential effectiveness of this outcome measure. How-
ever, it is acknowledged that currently in the haemodialy-
sis population the use of HGS focuses on changes within
the individual and further validation of HGS with the
production of standard tables for this population would
be advantageous prior to conducting a definitive trial.
Based on previous research, we have presented possible
sample sizes on a range of minimal clinically important
differences which should be useful when planning a
definitive trial.
Feasibility of a definitive trial
The trial would be feasible with these estimates as there
are over 70 dialysis units in the UK. However, a reduc-
tion of centres from 19 would seem more feasible andmanageable for a definitive trial. Simple, stratified ran-
domisation was used in this pilot which allowed feasibi-
lity outcomes to be assessed. However, consideration
could be given to the randomised withdrawal [35] or a
“1 month on” and “1 month off” method in a larger trial.
This would provide better outcomes regarding the
length of time an intervention is required to produce a
beneficial effect. For example, an ONS could be pro-
vided for a decreasing number of months in different
arms of the trial and difference in outcomes assessed or
could be provided for 1 month with an alternating
month of no ONS and again compare the results. This
could potentially reduce costs of providing such an
intervention in the longer term and also prevent taste
fatigue of the ONS. If the same benefit is seen after
2 months of supplementation as after 6 months, then
ONS could be given for shorter periods of time.
The integration of a nested, internal pilot in the defini-
tive trial should also be considered to allow continued
monitoring of the feasibility, in particular, the assessment
of using different inclusion criteria and the recommended
changes to the data collection methods, particularly within
the first year of recruitment. The use of a qualitative elem-
ent to assess the participants’ views on data collection
methods would also be beneficial.
The small sample size of this trial is a limitation, but
the results provide invaluable information regarding
feasibility of conducting a definitive trial of intradialytic
ONS in a UK haemodialysis population.
Conclusions
This study reports on the feasibility of conducting a ran-
domised trial of intradialytic ONS to assess the effect on
nutritional status. A definitive trial powered to detect a
change in handgrip strength would be feasible in the UK
population, with some adaptations to the protocol. The
study discusses aspects of the trial that would need
further consideration including the eligibility criteria,
adherence to the intervention and the choice of outcome
measures and assessments.
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